A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification — Stella
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California
University of Kansas Medical Center Research Institute, Kansas City, Kansas
Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland
The University of Texas Md Anderson Cancer Center, Houston, Texas
Australia
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales
Monash Health, Clayton, Victoria
Peter Maccallum Cancer Centre, Melbourne, Victoria
Linear Clinical Research, Nedlands, Western Australia
China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality
Beijing Cancer Hospital, Beijing, Beijing Municipality
Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi
New Zealand
Auckland City Hospital, Auckland
South Korea
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi
Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi